For research use only. Not for therapeutic Use.
Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2].
Alfuzosin hydrochloride (10 mg/kg, p.o.; single) potently antagonizes phenylephrine-induced increases in urethral and arterial pressures up to 6 hours post dosing[1].
| Catalog Number | I004956 |
| CAS Number | 81403-80-7 |
| Synonyms | N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide |
| Molecular Formula | C19H27N5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) |
| InChIKey | WNMJYKCGWZFFKR-UHFFFAOYSA-N |
| SMILES | CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC |
| Reference | [1]. Martin DJ, et al. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. 1998;63(3):169-76. [2]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. |
